Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2019

Open Access 01-12-2019 | Computed Tomography | Original research

Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis—an animal experimental prospective cohort study

Authors: Martin Mirus, Sergey V. Tokalov, Andrij Abramyuk, Jessica Heinold, Vincent Prochnow, Klaus Zöphel, Jörg Kotzerke, Nasreddin Abolmaali

Published in: EJNMMI Research | Issue 1/2019

Login to get access

Abstract

Background

This study investigated the noninvasive assessment of tumor vascularization with clinical F-18-fluorodeoxyglucose positron emission tomography/computed tomography and contrast-enhanced computed tomography ([18F]FDG-PET/CT and CE-CT) in experimental human xenograft tumors with modifiable vascularization and compared results to histology. Tumor xenografts with modifiable vascularization were established in 71 athymic nude rats by subcutaneous transplantation of human non-small-cell lung cancer (NSCLC) cells. Four different groups were transplanted with two different tumor cell lines (either A549 or H1299) alone or tumors co-transplanted with rat glomerular endothelial (RGE) cells, the latter to increase vascularization. Tumors were assessed noninvasively by [18F]FDG PET/CT and contrast-enhanced CT (CE-CT) using clinical scanners. This was followed by histological examinations evaluating tumor vasculature (CD-31 and intravascular fluorescent beads).

Results

In both tumor lines (A549 and H1299), co-transplantation of RGE cells resulted in faster growth rates [maximal tumor diameter of 20 mm after 22 (± 1.2) as compared to 45 (± 1.8) days, p < 0.001], higher microvessel density (MVD) determined histologically after CD-31 staining [171.4 (± 18.9) as compared to 110.8 (± 11) vessels per mm2, p = 0.002], and higher perfusion as indicated by the number of beads [1.3 (± 0.1) as compared to 1.1 (± 0.04) beads per field of view, p = 0.001]. In [18F]FDG-PET/CT, co-transplanted tumors revealed significantly higher standardized uptake values [SUVmax, 2.8 (± 0.2) as compared to 1.1 (± 0.1), p < 0.001] and larger metabolic active volumes [2.4 (± 0.2) as compared to 0.4 (± 0.2) cm3, p < 0.001] than non-co-transplanted tumors. There were significant correlations for vascularization parameters derived from histology and [18F]FDG PET/CT [beads and SUVmax, r = 0.353, p = 0.005; CD-31 and SUVmax, r = 0.294, p = 0.036] as well as between CE-CT and [18F]FDG PET/CT [contrast enhancement and SUVmax, r = 0.63, p < 0.001; vital CT tumor volume and metabolic PET tumor volume, r = 0.919, p < 0.001].

Conclusions

In this study, a human xenograft tumor model with modifiable vascularization implementable for imaging, pharmacological, and radiation therapy studies was successfully established. Both [18F]FDG-PET/CT and CE-CT are capable to detect parameters closely connected to the degree of tumor vascularization, thus they can help to evaluate vascularization in tumors noninvasively. [18F]FDG-PET may be considered for characterization of tumors beyond pure glucose metabolism and have much greater contribution to diagnostics in oncology.
Literature
1.
Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, et al. Tumor angiogenesis—therapeutic implications. N Engl J Med. 1971;285(21):1182–6.PubMedCrossRef
2.
3.
4.
5.
6.
MacManus M, Everitt S, Hicks RJ. The evolving role of molecular imaging in non-small cell lung cancer radiotherapy. Semin Radiat Oncol. 2015;25(2):133–42.PubMedCrossRef
7.
Cacicedo J, Navarro A, Del Hoyo O, Gomez-Iturriaga A, Alongi F, Medina JA, et al. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. Br J Radiol. 2016;89(1067):20160217.PubMedPubMedCentralCrossRef
8.
Wolf G, Abolmaali N. Imaging tumour-bearing animals using clinical scanners. Int J Radiat Biol. 2009;85(9):752–62.PubMedCrossRef
9.
Warburg O. On the metabolism of cancer cells. Naturwissenschaften. 1924;12:1131–7.CrossRef
10.
Mankoff DA, Bellon JR. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol. 2001;11(1):16–27.PubMedCrossRef
11.
12.
Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49(Suppl 2):24S–42S.PubMedCrossRef
13.
Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50(11):1820–7.PubMedPubMedCentralCrossRef
14.
Dubois LJ, Niemans R, van Kuijk SJ, Panth KM, Parvathaneni NK, Peeters SG, et al. New ways to image and target tumour hypoxia and its molecular responses. Radiother Oncol. 2015;116(3):352–7.PubMedCrossRef
15.
Danhier P, Banski P, Payen VL, Grasso D, Ippolito L, Sonveaux P, et al. Cancer metabolism in space and time: beyond the Warburg effect. Biochim Biophys Acta Bioenerg. 2017;1858(8):556–72.PubMedCrossRef
16.
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13(6):472–82.PubMedCrossRef
17.
Kwee TC, Gholami S, Werner TJ, Rubello D, Alavi A, Hoilund-Carlsen PF. 18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: do we need additional tracers for clinical purposes? Nucl Med Commun. 2016;37(4):333–7.PubMedCrossRef
18.
19.
20.
Tamura M, Unno K, Yonezawa S, Hattori K, Nakashima E, Tsukada H, et al. In vivo trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization. Life Sci. 2004;75(5):575–84.PubMedCrossRef
21.
Tokalov SV, Abolmaali ND. Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer. 2010;23:10.
22.
23.
Tokalov SV, Enghardt W, Abolmaali N. Tumour bed irradiation of human tumour xenografts in a nude rat model using a common X-ray tube. J Biosci. 2010;35(2):203–7.PubMedCrossRef
24.
Zutphen LFv, Hackbarth H. Grundlagen der Versuchstierkunde : ein Beitrag zum tierschutzgerechten Umgang mit Versuchstieren und zur Qualität tierexperimenteller Ergebnisse ; mit 38 Tabellen. 1. Aufl. ed. Stuttgart [u.a.]: G. Fischer 1995.
25.
Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J. 2008;49(1):17–26.PubMedCrossRef
26.
Wang SP, Zhou D, Yao Z, Satapati S, Chen Y, Daurio NA, et al. Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus. Am J Physiol Endocrinol Metab. 2016;311(6):E911–E21.PubMedCrossRef
27.
Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38(12):1564–79.PubMedCrossRef
28.
Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69(3):247–50.PubMedCrossRef
29.
La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1335–41.PubMedPubMedCentralCrossRef
30.
Cherk MH, Foo SS, Poon AMT, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by F-18-fluoromisonidazole and F-18-FDG PET. J Nucl Med. 2006;47(12):1921–6.PubMed
31.
32.
Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33(1):22–8.PubMedCrossRef
33.
Yang HJ, Xu WJ, Guan YH, Zhang HW, Ding WQ, Rong L, et al. Expression of Glut-1 and HK-II in pancreatic cancer and their impact on prognosis and FDG accumulation. Transl Oncol. 2016;9(6):583–91.PubMedPubMedCentralCrossRef
34.
35.
Choi WH, Yoo Ie R, O JH, Kim TJ, Lee KY, Kim YK. Is the glut expression related to FDG uptake in PET/CT of non-small cell lung cancer patients? Technol Health Care. 2015;23(Suppl 2):S311–8.PubMedCrossRef
36.
Zhang L, Sun H, Du S, Xu W, Xin J, Guo Q. Evaluation of 18F-FDG PET/CT parameters for reflection of aggressiveness and prediction of prognosis in early-stage cervical cancer. Nucl Med Commun. 2018;39(11):1045–52.PubMedCrossRef
37.
Chikamoto A, Inoue R, Komohara Y, Sakamaki K, Hashimoto D, Shiraishi S, et al. Preoperative high maximum standardized uptake value in association with glucose transporter 1 predicts poor prognosis in pancreatic Cancer. Ann Surg Oncol. 2017;24(7):2040–6.PubMedCrossRef
38.
Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25(4):317–22.PubMedCrossRef
39.
Mota LG, de Barros AL, Fuscaldi LL, de Souza CM, Cassali GD, Moghbel M, et al. Evolving role of radiolabeled particles in detecting infection and inflammation, preliminary data with 99mTc-phytate in rats. Nucl Med Commun. 2015;36(11):1113–9.PubMedCrossRef
40.
Fernandes RS, Mota LG, Kalbasi A, Moghbel M, Werner TJ, Alavi A, et al. 99mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors. Nucl Med Commun. 2015;36(10):1042–8.PubMedCrossRef
41.
Reiner CS, Goetti R, Burger IA, Fischer MA, Frauenfelder T, Knuth A, et al. Liver perfusion imaging in patients with primary and metastatic liver malignancy: prospective comparison between 99mTc-MAA spect and dynamic CT perfusion. Acad Radiol. 2012;19(5):613–21.PubMedCrossRef
42.
Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiation Oncology Biol Phys. 2009;73(4):1177–86.CrossRef
43.
Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B. Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int. 2008;101(4):480–4.PubMed
44.
45.
Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl). 2007;85(11):1175–86.CrossRef
46.
Gronroos TJ, Lehtio K, Soderstrom KO, Kronqvist P, Laine J, Eskola O, et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer. 2014;14:876.PubMedPubMedCentralCrossRef
47.
Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2–3):72–84.PubMedPubMedCentralCrossRef
48.
Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53(4):233–56.PubMedCrossRef
49.
Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.PubMedCrossRef
50.
Tixier F, Groves AM, Goh V, Hatt M, Ingrand P, Le Rest CC, et al. Correlation of intra-tumor 18F-FDG uptake heterogeneity indices with perfusion CT derived parameters in colorectal cancer. PLoS One. 2014;9(6):e99567.PubMedPubMedCentralCrossRef
51.
Cook GJR, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D. Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? J Nucl Med. 2013;54:19-26.PubMedCrossRef
52.
Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer. 2009;126(8):1777–87.CrossRef
53.
54.
55.
Xing N, Cai ZL, Zhao SH, Yang L, Xu BX, Wang FL. The use of CT perfusion to determine microvessel density in lung cancer: comparison with FDG-PET and pathology. Chin J Cancer Res. 2011;23(2):118–22.PubMedPubMedCentralCrossRef
56.
Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr. 2002;26(2):185–90.PubMedCrossRef
57.
Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, et al. Correlation between F-18-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med. 2011;52(5):705–11.PubMedCrossRef
58.
van Elmpt W, Das M, Huellner M, Sharifi H, Zegers CML, Reymen B, et al. Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiother Oncol. 2013;109(1):65–70.PubMedPubMedCentralCrossRef
59.
Sauter AW, Spira D, Schulze M, Pfannenberg C, Hetzel J, Reimold M, et al. Correlation between [F-18]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40(5):677–84.PubMedCrossRef
60.
Sauter AW, Winterstein S, Spira D, Hetzel J, Schulze M, Mueller M, et al. Multifunctional profiling of non small cell lung cancer using F-18-FDG PET/CT and volume perfusion CT. J Nucl Med. 2012;53(4):521–9.PubMedCrossRef
61.
Yokobori Y, Toyoda M, Sakakura K, Kaira K, Tsushima Y, Chikamatsu K. (18)F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. Acta Otolaryngol. 2015;135(5):494–9.PubMedCrossRef
62.
Abramyuk A, Tokalov S, Zophel K, Koch A, Szluha Lazanyi K, Gillham C, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol. 2009;91(3):399–404.PubMedCrossRef
63.
Nakajima R, Abe K, Kondo T, Tanabe K, Sakai S. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma. Eur Radiol. 2016;26(6):1852–62.PubMedCrossRef
64.
Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, et al. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. Eur J Nucl Med. 2001;28(6):704–10.PubMedCrossRef
65.
Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging. 2012;12:283–9.PubMedPubMedCentralCrossRef
66.
Yang Z, Zan Y, Zheng X, Hai W, Chen K, Huang Q, et al. Dynamic FDG-PET imaging to differentiate malignancies from inflammation in subcutaneous and in situ mouse model for non-small cell lung carcinoma (NSCLC). PLoS One. 2016;10(9):e0139089.CrossRef
67.
Schiffer WK, Mirrione MM, Dewey SL. Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents. J Nucl Med. 2007;48(2):277–87.PubMed
68.
Wong KP, Sha W, Zhang X, Huang SC. Effects of administration route, dietary condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice. J Nucl Med. 2011;52(5):800–7.PubMedPubMedCentralCrossRef
69.
Kim C, Kim IH, Kim SI, Kim YS, Kang SH, Moon SH, et al. Comparison of the intraperitoneal, Retroorbital and per Oral routes for F-18 FDG administration as effective alternatives to intravenous administration in mouse tumor models using small animal PET/CT studies. Nucl Med Mol Imaging. 2011;45(3):169–76.PubMedPubMedCentralCrossRef
70.
Stein AB, Tiwari S, Thomas P, Hunt G, Levent C, Stoddard MF, et al. Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res Cardiol. 2007;102(1):28–41.PubMedCrossRef
71.
Albrecht M, Henke J, Tacke S, Markert M, Guth B. Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats. BMC Vet Res. 2014;10:198.PubMedPubMedCentralCrossRef
72.
Sano Y, Ito S, Yoneda M, Nagasawa K, Matsuura N, Yamada Y, et al. Effects of various types of anesthesia on hemodynamics, cardiac function, and glucose and lipid metabolism in rats. Am J Physiol Heart Circ Physiol. 2016;311(6):H1360–H6.PubMedCrossRef
Metadata
Title
Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis—an animal experimental prospective cohort study
Authors
Martin Mirus
Sergey V. Tokalov
Andrij Abramyuk
Jessica Heinold
Vincent Prochnow
Klaus Zöphel
Jörg Kotzerke
Nasreddin Abolmaali
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2019
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-019-0502-0

Other articles of this Issue 1/2019

EJNMMI Research 1/2019 Go to the issue

Original research

Low septal to lateral wall 18F-FDG ratio is highly associated with mechanical dyssynchrony in non-ischemic CRT candidates

Original research

A phase 1, first-in-human study of 18F-GP1 positron emission tomography for imaging acute arterial thrombosis

Original research

[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

Original research

A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT

Original research

Impact of acquisition time and penalizing factor in a block-sequential regularized expectation maximization reconstruction algorithm on a Si-photomultiplier-based PET-CT system for 18F-FDG

Original research

Phase analysis single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) detects dyssynchrony in myocardial scar and increases specificity of MPI